GPT-3? Happy April Fools Day. Brandon
> On Mar 31, 2021, at 9:47 PM, Alex Balashov <[email protected]> wrote: > > For immediate release: > > GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership with > Posner | Palner Pharmaceuticals, are pleased to announce the eagerly > anticipated start of Phase III clinical trials of Kamailio DMQ module > replication. > > In this stage of the investigation of the promising replication scheme, which > was developed in record time, DMQ will be tested in a rigourous, double-blind, > controlled CI/CD process for large-scale efficacy and continually monitored > for > safety in shorter and longer terms. > > The now-concluded second phase established basic safety and Phase 2b entailed > a > dose-finding study for the optimal number of batched `dmq_usrloc` contacts per > kilogram of cloud computing resource. > > The main cohort of the main sequence of the Phase III trial will enroll 380 > randomly selected, statistically representative Floridian SIP registrars and > 5700 SIP dialogs, also in the state of Florida. When asked about the disparity > in the number of registrars versus dialogs, Alex Balashov of Evariste said, > "It > is reflective of the small number of SIP registrars in Florida; not to be > indelicate, but consider the median age of the population." > > As previously remarked upon in proceedings of the World SIP Organisation > (WSO), > the choice of Florida as a venue attracted some questions. We asked Fred > Posner > of Posner | Palner about the clinical background informing this choice of > replication study cohort: > > "Florida is a good place to find eventual consistency failures; the open > climate and reluctance to accept traditional data integrity science would have > sealed the deal, but when people started to drink bleach here, I saw an > opportunity." > > Evariste and Posner | Palner are aiming for a US Food & Drug Administration > EUA > (Emergency Use Authorisation) for DMQ replication as a prophylactic data > redundancy and failover measure to ward off the development of moderate to > severe viral Sonus Haemorrhagic Fever symptoms. > > Phase II studies have painted a promising a picture of the DMQ architecture's > ability to reduce moderate to severe symptoms and associated 28-day mortality > by more than 90%, albeit over a small sample size and in enterprise patients > with known pre-existing comorbidities such as Session Border Controller and > BroadSoft Multi-System Inflammatory Syndrome. Phase III trials seek to > bolster > quantums of broader efficacy, including efficacy for localised outbreaks of > small to medium business softswitch. > > Of the control group, Balashov said, "They will receive a standard > pipe-to-/dev/null placebo protocol, but with identical '200 OK' confirmation > messages. We proudly developed this approach in early 2020 in consultation > with > the highest levels of the Trump presidential administration; it is called > TENP, or 'The Emperor's New Potion.' It is a successor to that > administration's > previous approved placebo protocol, SHTI - Small Hands, Tremendous > Initiatives." > > Despite speculative autism and packet fragmentation claims by Florida Governor > Ron DeSantis, Balashov was quick to provide reassurance about side effects > from > DMQ in the Phase III trial. > > "The incidence of severe allergies to plain-text UDP was within standard > deviation over the mean for all insecure replication, and there's support for > other transports on the way. Anyway, we have a robust adverse effects > reporting > system in our issue tracker and solid surveillance. Don't let partisan > politics > dissuade you from allowing request lines with the KDMQ method." > > Other industry sources have reported that DMQ is not the only replication > investigation undertaken by Evariste and Posner | Palner, although it is the > only > prophylactic suitable for the early infection development and inflammatory > phases of a broad class of SBC-complex syndromes typically afflicting service > providers. A recent IETF preprint by the same authors has shown high-quality > preliminary data suggesting statistically significant improvement in morbidity > outcomes from Perimeta and Nokia via a later-stage therapeutic intervention > with a monoclonal, monorepo Github cocktail administered intravenously. > > > -- > Alex Balashov | Principal | Evariste Systems LLC > > Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free) > Web: http://www.evaristesys.com/, http://www.csrpswitch.com/ > _______________________________________________ > VoiceOps mailing list > [email protected] > https://puck.nether.net/mailman/listinfo/voiceops _______________________________________________ VoiceOps mailing list [email protected] https://puck.nether.net/mailman/listinfo/voiceops
